Pharmacogenetics: Progress, pitfalls and clinical potential for coronary heart disease

Vascular Pharmacology

Volumn 44, Issue 2, 2006, Pages 119-125

  Humphries, Steve E ^a   Hingorani, Aroon ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adverse drug response; CETP; CYP2C9; Statins; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; PRAVASTATIN; WARFARIN;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; GENE LOCUS; GENE MUTATION; GENE REPLICATION; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MYALGIA; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; STROKE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS; CORONARY DISEASE; GENETIC SCREENING; GENOTYPE; HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; WARFARIN;

EID: 30544449390     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.10.003     Document Type: Review

References (33)

1. F. Basso, G.D. Lowe, A. Rumley, A.D. Mcmahon, and S.E. Humphries Interleukin-6-174G>C polymorphism and risk of coronary heart disease in west of Scotland coronary prevention study (WOSCOPS) Arterioscler. Thromb. Vasc. Biol. 22 2002 599 604
2. S.M. Boekholdt, F.M. Sacks, J.W. Jukema, J. Shepherd, D.J. Freeman, A.D. McMahon, F. Cambien, V. Nicaud, G.J. de Grooth, P.J. Talmud, S.E. Humphries, G.J. Miller, G. Eiriksdottir, V. Gudnason, H. Kauma, S. Kakko, M.J. Savolainen, M. Arca, A. Montali, S. Liu, H.J. Lanz, A.H. Zwinderman, J.A. Kuivenhoven, and J.J.P. Kastelein Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects Circulation 111 2005 278 287
3. D.J. Brull, H.E. Montgomery, J. Sanders, S. Dhamrait, L.-A. Luong, A. Rumley, G.D.O. Lowe, and S.E. Humphries Interleukin-6 gene-174G > C and -572G > C promoter polymorphisms are strong predictors of plasma IL-6 levels after coronary artery bypass surgery Arterioscler. Thromb. Vasc. Biol. 21 2001 1458 1463
4. D.I. Chasman, D. Posada, L. Subrahmanyan, N.R. Cook, V.P. Stanton Jr., and P.M. Ridker Pharmacogenetic study of statin therapy and cholesterol reduction J. Am. Med. Assoc. 291 2004 2821 2827
5. H.M. Colhoun, P.M. McKeigue, and S.G. Davey Problems of reporting genetic associations with complex outcomes Lancet 361 2003 865 872
6. O.P. Corrigan Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report J. Med. Ethics 31 2005 144 148
7. K.A. Dornbrook-Lavender, and J.A. Pieper Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy Cardiovasc. Drugs Ther. 17 2003 75 82
8. D. Fishman, G. Faulds, R. Jeffery, V. Mohamed Ali, J.S. Yudkin, S. Humphries, and P. Woo The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis J. Clin. Invest. 102 1998 1369 1376
9. J.L. Georges, V. Loukaci, O. Poirier, A. Evans, G. Luc, D. Arveiler, J.B. Ruidavets, F. Cambien, and L. Tiret Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde J. Mol. Med. 79 2001 300 305
10. D.B. Goldstein, K.R. Ahmadi, M.E. Weale, and N.W. Wood Genome scans and candidate gene approaches in the study of common diseases and variable drug responses Trends Genet. 19 2003 615 622
11. K.E. Heath, V. Gudnason, S.E. Humphries, and M. Seed The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia Atherosclerosis 143 1999 41 54
12. S.E. Humphries, L.-A. Luong, M.S. Ogg, E. Hawe, and G.J. Miller The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men Eur. Heart J. 22 2001 2243 2252
13. S.E. Humphries, P.M. Ridker, and P.J. Talmud Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler. Thromb. Vasc. Biol. 24 2004 628 636
14. S.M. Jamal, M.J. Eisenberg, and S. Christopoulos Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors Am. Heart J. 147 2004 956 965
15. M. Jeenah, W. September, v.R. Graadt, W. de Villiers, H. Seftel, and D. Marais Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia Atherosclerosis 98 1993 51 58
16. K.G. Jones, D.J. Brull, L.C. Brown, M. Sian, R.M. Greenhalgh, S.E. Humphries, and J.T. Powell Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms Circulation 103 2001 2260 2265
17. K. Kajinami, N. Takekoshi, M.E. Brousseau, and E.J. Schaefer Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management Atherosclerosis 177 2004 219 234
18. S. Kilpinen, J. Hulkkonen, X.Y. Wang, and M. Hurme The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults Eur. Cytokine Netw. 12 2001 62 68
19. J. Kirchheiner, and J. Brockmoller Clinical consequences of cytochrome P450 2C9 polymorphisms Clin. Pharmacol. Ther. 77 2005 1 16
20. J.A. Kuivenhoven, J.W. Jukema, A.H. Zwinderman, P. de Knijff, R. McPherson, A.V. Bruschke, K.I. Lie, and J.J. Kastelein The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group N. Engl. J. Med. 338 1998 86 93
21. E. Mokwe, S.E. Ohmit, S.A. Nasser, T. Shafi, E. Saunders, E. Crook, A. Dudley, and J.M. Flack Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial Hypertension 43 6 2004 1202 1207
22. M.S. Ogg, P. Brennan, T. Meade, and S.E. Humphries CYP2C9*3 allelic variant and bleeding complications Lancet 354 1999 1124
23. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N. Engl. J. Med. 336 1997 973 979
24. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 1999 230 235
25. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N. Engl. J. Med. 342 2000 836 843
26. S. Sanderson, J. Emery, and J. Higgins CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis Genet. Med. 7 2005 97 104
27. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam. Clin. Pharmacol. 19 2005 117 125
28. S. Senn Individual response to treatment: is it a valid assumption? Br. Med. J. 329 2004 966 968
29. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. Macfarlane, J.H. McKillop, and C.J. Packard Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group N. Engl. J. Med. 333 1995 1301 1307
30. S.K. Tate, and D.B. Goldstein Will tomorrow's medicines work for everyone? Nat. Genet. 36 2004 S34 S42
31. The Medical Research Council's General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose asprin in the primary prevention of ischaemic heart disease in men at increased risk Lancet 351 1998 233 241
32. J.H. You, F.W. Chan, R.S. Wong, and G. Cheng The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy-a decision analysis Thromb. Haemost. 92 2004 590 597
33. J.S. Yudkin, M. Kumari, S.E. Humphries, and V. Mohamed-Ali Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148 2000 209 214